EcoDrugPlus

Folate Receptor Beta

Ensembl ID : ENSLOCG00000007764
Gene Symbol: FOLR2
3 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSLOCG00000016280
Gene Symbol: FSHR
2 Cross references
200 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSLOCG00000016973
Gene Symbol: FRK
3 Cross references
216 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSLOCG00000015326
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin 3

Ensembl ID : ENSLOCG00000011769
Gene Symbol: LGALS3
3 Cross references
160 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha1 Subunit

Ensembl ID : ENSLOCG00000010698
Gene Symbol: GABRA1
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha2 Subunit

Ensembl ID : ENSLOCG00000012384
Gene Symbol: GABRA2
3 Cross references
255 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha4 Subunit

Ensembl ID : ENSLOCG00000012374
Gene Symbol: GABRA4
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSLOCG00000013763
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSLOCG00000008325
Gene Symbol: GABRA5
3 Cross references
266 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6a

Ensembl ID : ENSLOCG00000010706
Gene Symbol: GABRA6A
1 Cross references
195 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSLOCG00000011649
Gene Symbol: GABRB1
4 Cross references
102 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).